Atara Biotherapeutics: 2 New Catalysts To Fuel Further Growth

|
About: Atara Biotherapeutics, Inc. (ATRA)
by: BioSci Capital Partners
This article is exclusive for subscribers.
BioSci Capital Partners
Integrated BioSci Investing
BECOME AN EXPERT BIO-INVESTOR WITH THE COLUMBIA DOC/SCIENTIST/MARKET WHIZ
Summary

Atara is hitting its growth inflection by the powering of multiple catalysts.

Company recently deepened its research relationship with Memorial Sloan Kettering; partnered with TrakCel for Atara MatchMe; completed the Atara T Cell Operations & Manufacturing facility; and strengthened the balance sheet.

Utpal Koppikar joined as the new CFO. New research finding further supports the underlying science of Atara’s multiple sclerosis franchise (ATA-188 and ATA-190).

You need to have a passionate interest in why things are happening. That cast of mind, kept over long periods, gradually improves your ability to focus on reality. If you don't have the cast of